Abstract
We demonstrate that the designed ankyrin repeat protein (DARPin)-9-29, which specifically targets human epidermal growth factor receptor 2 (HER 2), binds tightly to gold nanoparticles (GNPs). Binding of the protein strongly increases the colloidal stability of the particles. The results of experimental analysis and molecular dynamics simulations show that approximately 35 DARPin-9-29 molecules are bound to the surface of a 5 nm GNP and that the binding does not involve the receptor-binding domain of the protein. The confocal fluorescent microscopy studies show that the DARPin-coated GNP conjugate specifically interacts with the surface of human cancer cells overexpressing epidermal growth factor receptor 2 (HER2) and enters the cells by endocytosis. The high stability under physiological conditions and high affinity to the receptors overexpressed by cancer cells make conjugates of plasmonic gold nanostructures with DARPin molecules promising candidates for cancer therapy.
| Original language | English |
|---|---|
| Pages (from-to) | 2569-2574 |
| Number of pages | 6 |
| Journal | Bioconjugate Chemistry |
| Volume | 28 |
| Issue number | 10 |
| DOIs | |
| Publication status | Published - 18 Oct 2017 |
Fingerprint
ASJC Scopus subject areas
- Biotechnology
- Bioengineering
- Biomedical Engineering
- Pharmacology
- Pharmaceutical Science
- Organic Chemistry
Cite this
Synthesis, Characterization, and Selective Delivery of DARPin-Gold Nanoparticle Conjugates to Cancer Cells. / Deyev, Sergey; Proshkina, Galina; Ryabova, Anastasiya; Tavanti, Francesco; Menziani, Maria Cristina; Eidelshtein, Gennady; Avishai, Gavriel; Kotlyar, Alexander.
In: Bioconjugate Chemistry, Vol. 28, No. 10, 18.10.2017, p. 2569-2574.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Synthesis, Characterization, and Selective Delivery of DARPin-Gold Nanoparticle Conjugates to Cancer Cells
AU - Deyev, Sergey
AU - Proshkina, Galina
AU - Ryabova, Anastasiya
AU - Tavanti, Francesco
AU - Menziani, Maria Cristina
AU - Eidelshtein, Gennady
AU - Avishai, Gavriel
AU - Kotlyar, Alexander
PY - 2017/10/18
Y1 - 2017/10/18
N2 - We demonstrate that the designed ankyrin repeat protein (DARPin)-9-29, which specifically targets human epidermal growth factor receptor 2 (HER 2), binds tightly to gold nanoparticles (GNPs). Binding of the protein strongly increases the colloidal stability of the particles. The results of experimental analysis and molecular dynamics simulations show that approximately 35 DARPin-9-29 molecules are bound to the surface of a 5 nm GNP and that the binding does not involve the receptor-binding domain of the protein. The confocal fluorescent microscopy studies show that the DARPin-coated GNP conjugate specifically interacts with the surface of human cancer cells overexpressing epidermal growth factor receptor 2 (HER2) and enters the cells by endocytosis. The high stability under physiological conditions and high affinity to the receptors overexpressed by cancer cells make conjugates of plasmonic gold nanostructures with DARPin molecules promising candidates for cancer therapy.
AB - We demonstrate that the designed ankyrin repeat protein (DARPin)-9-29, which specifically targets human epidermal growth factor receptor 2 (HER 2), binds tightly to gold nanoparticles (GNPs). Binding of the protein strongly increases the colloidal stability of the particles. The results of experimental analysis and molecular dynamics simulations show that approximately 35 DARPin-9-29 molecules are bound to the surface of a 5 nm GNP and that the binding does not involve the receptor-binding domain of the protein. The confocal fluorescent microscopy studies show that the DARPin-coated GNP conjugate specifically interacts with the surface of human cancer cells overexpressing epidermal growth factor receptor 2 (HER2) and enters the cells by endocytosis. The high stability under physiological conditions and high affinity to the receptors overexpressed by cancer cells make conjugates of plasmonic gold nanostructures with DARPin molecules promising candidates for cancer therapy.
UR - http://www.scopus.com/inward/record.url?scp=85031812187&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85031812187&partnerID=8YFLogxK
U2 - 10.1021/acs.bioconjchem.7b00410
DO - 10.1021/acs.bioconjchem.7b00410
M3 - Article
VL - 28
SP - 2569
EP - 2574
JO - Bioconjugate Chemistry
JF - Bioconjugate Chemistry
SN - 1043-1802
IS - 10
ER -